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1. Introduction
Dystonia and Spasticity, both clinically manifesting with muscle hyperactivity, are symp-
tomatic targets for Botulinum toxin (mainly type A, and referred to here as BoNT) injection. 
Certain differences exist in their phenomenology and complexity, hence the need to highlight 
those intricacies, as relevant in the clinics. This introductory chapter therefore aims to provide 
a framework upon which the practical applications of BoNT in dystonia and spasticity may be 
applied in contemporary times. The other chapters in this book will likewise discuss aspects 
of BoNT from the basic to the clinical side, including the current use of instrument-guided 
injections and tandem neuro-rehabilitation.
2. Dystonia Phenomenology
The contemporary definition and phenomenology of dystonia, bears the following key points, 
as derived from Movement Disorders Society:
(1) “Dystonia is a movement disorder characterized by sustained or intermittent muscle 
contractions causing abnormal, often repetitive, movements, postures, or both. Dystonic 
movements are typically patterned, twisting, and may be tremulous. Dystonia is 
often initiated or worsened by voluntary action and associated with overflow muscle 
activation.”
(2) Phenomenology of dystonia includes influence of voluntary action, tremor occur-
rence, motor overflow and mirror movements.
(3) Alleviating maneuvers to reduce or abolish dystonia.
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A Multi-axial diagnostic approach for dystonia includes the following:
(1) Axis I (Clinical characteristics): Age of onset, body distribution, temporal pattern and 
associated features.
(2) Axis II (Etiology): Nervous system pathology, inherited, acquired or idiopathic.
(3) Treatment of dystonia range from oral medications, chemodenervation (with BoNT and 
muscle afferent block), neurorehabilitation and functional surgery.
3. Botulinum Toxin for Dystonia
BoNT, as applied in dystonia is well established for focal, segmental and task-specific dys-
tonias. The advantage of BoNT in dystonia is hinged on the following: (1) Dual mechanistic 
effects of BoNT along extrafusal (hence in muscle hyperactivity) and intrafusal (hence in pos-
turing and muscle afferent modulatory effects along spinal and supraspinal networks) muscles; 
(2) Targeted therapy in focal muscular spasms; (3) Aims that improve quality of life and func-
tioning; (4) “Tailored fit” based on the variable dystonic patterns; and (5) Repeated but robust 
and safe injections over time. In fact, BoNT may be considered as a “sensory trick” acting via 
proprioceptors, that not only alleviate muscle spasms at injected, but also contiguous areas in 
overflow. The usual aims of BoNT in dystonia range from relief of spasms, improve posture, 
pain reduction, cosmesis, and prevention of contractures, bone and joint instability, dislocation 
and occurrence of radiculopathy. BoNT may still have roles in generalized dystonias, where 
AD, adjuvant drugs; ADD, antidystonic drugs; BTT, botulinum toxin therapy; DBS, deep brain stimulation; RT, 
rehabilitation therapy: physiotherapy, re-training, occupational therapy, speech therapy, sociotherapy, psychotherapy, 
patients groups. 
Table 1. Algorithm for treatment of dystonia.
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specific aims are geared to improve quality of life and functioning. An example will be BoNT 
for oro-mandibulo-lingual dystonias aimed at feeding and nutrition. In addition, BoNT in 
dystonia may still be combined with onboard oral medications and even following functional 
neurosurgery.
Neurological Practice Guidelines forwarded by the American Academy and European 
Federation indicated Level A Recommendation for BoNT in Focal dystonias, especially bleph-
arospasm, cervical dystonia and writer’s cramp. Likewise, recommendations based on dys-
tonia severity, applying a number of management strategies, have been recently published 
by the IAB—Interdisciplinary Working Group for Movement Disorders Special Task Force 
on Interdisciplinary Treatment of Dystonia (Table 1 from Dressler et al, Journal of Neural 
Transmission, 2015, with permission).
4. Spasticity and its Complexity
Spasticity may complicate stroke, multiple sclerosis (MS), cerebral palsy (CP), traumatic brain 
injury (TBI), spinal cord injury, hereditary spastic paraplegia a well as retroviral and other 
infectious spinal cord disorders.
Spasticity, as it arises from the involuntary activation of muscles, whether intermittent or con-
tinuous, may lead to pain, disability, functional impairment and eventually contractures. In 
the case of stroke, about a third of survivors have significant post-stroke spasticity (PSS) and 
among those presenting in the hospital, about half develop at least one severe contracture.
Being a complex condition, spastic paresis substantially impacts on patients’ and caregivers’ 
quality of life. Hence, spasticity management may engage interdisciplinary sub-specialties. To 
date, the varied rehabilitation practices in spasticity are generally aimed at prevention of sec-
ondary complications, minimizing aggravating factors, perhaps losing focus on the abnormal 
muscle activity itself. For instance, it is now understood that the critical factor in movement 
impairment in spastic paresis is the overall involvement of antagonist resistance, whether of a 
reflex nature or not. In addition, a wider problem area in spasticity is the fact that management 
should also address spasticity-related co-contraction, dystonia, associated reactions, local bio-
mechanical changes and contracture. This present work aims to show how, incorporating BoNT 
injection in neurorehabilitation practices, could pave the available treatment avenues toward 
improving, not only muscle tone, but also other related disabilities of the paretic limb afflicted 
with spasticity. Majority of the discussions made hereinunder were based on our summary 
works on the subjects of PSS (including non-progressive brain lesions like TBI), MS and CP 
(suggested readings given). We also incorporated the recently published practice guidelines on 
the use of BoNT for adult spasticity, put forth by the American Academy of Neurology, as well 
as an updated systematic review of CP management (additional readings given).
5. Botulinum Toxin for Treatment Goals in Spasticity
BoNT has withstood the test of time, being an efficacious and safe symptomatic therapy for 
chronic spasticity, hinged from meta-analyses derived from well-conducted, randomized con-
trolled clinical trials. Thus, BoNT, in combination with neurorehabilitation, is considered a first 
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line treatment in focal and multifocal spasticity, both in adults and children. Pharmacologic 
BoNT presynaptic cholinergic blockading effects may be seen not only in extrafusal muscles, 
but also the intrafusal muscles, leading to a modulation of afferent signals to the spinal and 
supra-spinal levels. This dual blockade mechanism of action of BoNT attains clinical signifi-
cance in the spasticity state where increased muscle tone and stretch reflexes occur.
Targeted use of BoNT in established spasticity should be hinged on realistic goals that will 
facilitate reduction of muscle tone and pain, improve passive limb functions (e.g. dressing, 
hygiene, cosmesis) and facilitate in tandem neurorehabilitation. Goal Attainment Scaling 
(GAS) may be the ideal way to assess success of BoNT injection, in that the pre-defined aims 
are gleaned to be person-centered, realistic and achievable. Injection protocols for BoNT 
should be flexible and “tailor fit” for subsequent and repeat cycle injections, considering 
that goals may change over time. Muscle selection with avoidance of compensatory muscles, 
proper dosing and dilutions, appropriate injection delivery and guidance, initial and post-
injection established protocols and awareness of contraindicated disorders (e.g. neuromus-
cular junction disorders) should all factor in, to optimize efficacy. Improvement in active 
function (not so achievable to date) with established upper limb spasticity is a fair desire 
from both the patient and the clinician, however, one may have to incorporate the injections 
with an interdisciplinary team approach. In CP, patients who are malnourished and who are 
having oropharyngeal dysfunction, pseu-dobulbar palsy and a high Gross Motor Function 
Classification.
System (GMFCS) level are considered a high risk group for BoNT injection complications. 
In the case of MS, being an immune-mediated process, reviews state a principal suitability 
of BoNT for treatment of spasticity. An added benefit could be explored on how BoNT may 
potentially impact on the accompanying pain in MS, other than spasticity. Included in this 
present book are dedicated chapters on instrumentation-guided BoNT injections and rehabili-
tation practices in adults and children with spasticity.
6. Botulinum Toxin For Spasticity and its Associated Impairments
BoNT is a powerful treatment to address associated spasticity impairments, in that the toxin 
could be targeted to a muscle or muscle groups. These impairments are:
(1) Spastic co-contraction: inappropriate antagonist recruitment brought about by the voli-
tional command on an agonist, while stretch is absent. Possibly present in usual motor 
movement, an excessive simultaneous co-activation of agonist and antagonist muscles 
in spastic paresis may occur. Muscle over-activity may predominate in some muscles in 
spastic paresis, causing agonist–antagonist imbalance. BoNT may potentially restore the 
balance around joints by focally reducing muscle over activity;
(2) Spastic dystonia: stretch-sensitive tonic muscle contraction in the absence of voluntary 
command to adjacent muscles and in the absence of phasic stretch of the affected mus-
cles. As a consequence, it may alter the resting posture, while contributing to defor-
mity and impairment of passive function. BoNT targeted to over-active muscle groups, 
Botulinum Toxin Therapy Manual for Dystonia and Spasticity6
together with muscle lengthening, could raise stretch receptor recruitment threshold 
in the affected muscles and therefore reduce the severity of these potentially disabling 
forms of over-activity. In fact, it may well be, that this could be the best indication for 
BoNT injection as it addresses both phenomena of spasticity and dystonia altogether;
(3) Associated reactions: abnormal postural reactions (usually in upper limbs) seen on the 
hemiplegic side. These movements may posturally affect movement, as these are pur-
poseless. Past BoNT studies targeting these undesired movements have allowed more 
gain in functionality amongst affected individuals, and in fact, the said improvement 
may become a measure of patient progression;
(4) Local biomechanical changes and contractures: musculo-skeletal mechanical changes 
occurring during early immobilization in an upper motor neuron syndrome that may 
augment resistance to passive movements, potentially increasing resting discharge of 
muscle spindles and eventually their stretch sensitivity. Left unattended, muscle con-
tracture occurs by similar adaptations. In these subset of patients, muscle contracture 
contributes significantly to hypertonia. BoNT early injections in PSS and non-progressive 
brain lesions (<3 months), potentially modify the course of spasticity evolution, and per-
haps prevent the disabling consequences of immobilization and contracture.
7. Optimization of bont effects in spasticity
The American Academy of Neurology gave a Grade A recommendation for BoNT in the treat-
ment of spasticity in adults and in spasticity in CP. Together with neurorehabilitation, BoNT 
injections into the shorter of the two co-contracting muscles around the joint can augment 
stretching activities. Evidences exist on how BoNT injections indirectly modulate sensorimo-
tor loops at the spinal and supra-spinal levels and to which end, it has the capability to modify 
the course and progression of spasticity, especially in early PSS interventions. The goals do 
change in chronic spasticity and the person-centered GAS, has been proven to optimize BoNT 
effects, under time-monitored endpoints.
The optimal time to best administer BoNT in either or both affected hemiparetic limbs, would 
be when spasticity becomes established, impeding passive and active functions, occurrence 
of associated reactions and pain, while impairing patient quality of life (as is true with carer 
burden). On the other hand, early BoNT injections potentially extend window time for motor 
re-learning with physiotherapy. In effect, the early BoNT intervention paradigm may poten-
tially modify the natural progress of spasticity, prevent spasticity/dystonia-related complica-
tions or even delay re-injection.
Interestingly, a multi-modal therapeutic approach in spasticity will likely be a good model for 
optimizing care. Among others, those that are promising include combining BoNT injections 
with the following: (a) intensive occupational therapy and low-frequency repetitive transcra-
nial magnetic stimulation; (b) constraint-induced movement therapy; and (c) high intensity 
ambulatory rehabilitation programs.
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8. Conclusion and recommendation
Spasticity often requires consequent treatment. Therapeutic nihilism may produce devastating 
long-term complications. An interdisciplinary approach combines BoNT and rehabilitation. 
Recommendations are robust on the use of BoNT as a symptomatic therapy for PSS, non-pro-
gressive brain lesions, CP and MS. Carefully defined treatment goals are pivotal to achieve 
optimal outcomes and to optimize care practices. After developing the injection scheme, cor-
rect BoNT placement into the target muscles remains a major challenge. Recommended prac-
tice points to take home, when applying BoNT in spasticity, are summarized in the Table.
Recommended 10-Point Practice Guides in Botulinum toxin Injections (BoNT) for Spasticity:
(1) BoNT injections are given strong recommendations for spasticity after stroke and non-
progressive brain lesions, multiple sclerosis and cerebral palsy;
(2) BoNT therapy is best indicated (based on contemporary guidelines) in chronic focal spas-
ticity to reduce hypertonicity (and pain), improvement in disability (passive more than 
active functions), patient (and care-giver) quality of life and realistic person-centered 
goals;
(3) BoNT early interventions protocols (< 3 months from ictus) may modify spasticity pro-
gression, prevent contracture and delay re-injection;
(4) BoNT therapy may potentially restore the balance around joints by focally reducing 
muscle over-activity in spastic co-contraction, spastic dystonia and associated reactions;
(5) BoNT therapy should be part of a multi-modal or tandem neurorehabilitation practices 
to optimize achievement of goals;
(6) BoNT injections should be flexible and “tailor fit” for subsequent and repeat cycle injec-
tions, considering that goals may change;
(7) BoNT targeting, while applying appropriate and timely muscle selections, are key ele-
ments in injection success;
(8) BoNT delivery by instrumentation-guidance (e.g. ultrasound, electromyography and 
electrical stimulation) may further optimize injection practices;
(9) BoNT correct dosing and appropriate dilutions are important guides during injections 
(e.g. “high potency, low dilutions” to localize/maximize desired effects in small forearm 
and hand and foot muscles; “low potency, high dilutions” intended to spread the toxin 
in large arm, thigh and leg muscles);
(10) BoNT caveats in injection include: over-enthused injections in spasticity-protective mus-
cles (e.g. postural thigh muscles), compensatory muscles, concomitant neuromuscular 
junction disorders, frail and malnourished children or those with high Gross Motor 
Function Classification System.
Botulinum Toxin Therapy Manual for Dystonia and Spasticity8
Author details
Raymond L. Rosales1* and Dirk Dressler2
*Address all correspondence to: rlrosalesmd88@gmail.com
1 Department of Neurology and Psychiatry, University of Santo Tomas, Manila, Philippines
2 Movement Disorders Section, Department of Neurology, Hannover Medical School, 
Hannover, Germany
Suggested readings
[1] D. Dressler, E. Altenmueller, R. Bhidayasiri, S. Boholega, ,P. Chana, T.M. Chung, S. Frucht, 
P.J. Garcia-Ruiz, A. Kaeli, R. Kaji, P. Kanovsky, R. Laskawi, F. Micheli, O. Orlova, M. Relja, 
R.L.  Rosales, J. Slawek, S. Timerbaeva, T.T. Warner, F.A. Saberi: Strategies for treatment of 
dystonia. Journal of Neural Transmission. DOI: 10.1007/s00702-015-1453-x
[2] D. Dressler, R. Bhidayasiri, S. Bohlega, A. Chahidi, T.M. Chung, M. Ebke, J. Jacinto, R. 
Kaji, S. Kocer, P. Kanovsky, F. Micheli, O. Orlova, S. Paus, Z. Pirtosek, M. Relja, R.L. 
Rosales, J.A. Sagastegui-Rodrıguez, P.W. Schoenle, G.A. Shahidi, S. Timerbaeva, U. 
Walter, F.A. Saberi: Botulinum toxin therapy for treatment of spasticity in multiple 
sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group 
for Movement Disorders task force. Journal of Neurology, October 2016, DOI: 10.1007/
s00415-016-8304-z
[3] K. Fheodoroff, J. Jacinto, A.  Geurts, F. Molteni, J.H. Franco, T. Santiago, R.L. Rosales, 
J.M. Gracies: How Can We Improve Current Practice in Spastic Paresis? European 
Neurological Reviews, 2016;11:ePub ahead of print.
[4] M.A.L.P Gozum and R.L. Rosales: Botulinum Toxin A therapy in Early Post-
Stroke Spasticity: Providing a wider treatment avenue. Internaional Journal of 
NeuroRehabilitation 3(3), 2016 http://dx.doi.org/10.4172/2376-0281.1000207
[5] M. Lukban, R.L. Rosales, D. Dressler: Effectiveness of Botulinum Toxin A for Upper 
and Lower Limb Spasticity in Children with Cerebral Palsy: A Summary of  Evidence. 
Journal of Neural Transmission 116: 319-331, 2009.
[6] P. Kanovsky, K. Bhatia, R.L. Rosales (editors):  Dystonia and dystonic syndromes;  Springer, 
GmbH, Germany (2015) ISBN 978-3-7091-1515-2 ISBN 978-3-7091-1516-9 (eBook) DOI: 
10.1007/978-3-7091-1516-9
[7] R.L. Rosales (Chapter-8): Dystonia, Spasticity and Botulinum Toxin Therapy: Rationale, 
Evidences and Clinical Context; In: R.L. Rosales (Editor). Dystonia: The Many Facets.
(Intech Open Access Publishers, Croatia), 2012, ISBN: 978-953-307-1116-8 (www.inte-
chopen.com) (pp. 83-98).
Introductory Chapter: Botulinum Toxin Type A Therapy in Dystonia and Spasticity - What are Current...
http://dx.doi.org/10.5772/66706
9
[8] R.L. Rosales and A. Chua-Yap: Evidence-based systematic review on the efficacy 
and safety of botulinum toxin therapy in post-stroke spasticity. Journal of Neural 
Transmission 115 (4): 617-623, 2008.
[9] R.L. Rosales, D. Dressler: On muscle spindles, dystonia and botulinum toxin. European 
Journal of Neurology  17 (Suppl. 1): 71–80, 2010.
[10] R.L. Rosales, F. Efendy, E.S. Teleg, M.M.D. Delos Santos, M.C.E. Rosales, M. Ostrea , M.J. 
Tanglao, A.R. Ng: Botulinum toxin as early intervention for spasticity after stroke or 
non-progressive brain lesion: A meta-analysis. Journal of the Neurological Sciences 371: 
6–14, 2016 http://dx.doi.org/10.1016/j.jns.2016.10.005
[11] R.L. Rosales, P. Kanovsky, H.H. Fernandez: What’s the “catch” in upper-limb post-
stroke spasticity: Expanding the role of botulinum toxin applications, Parkinsonism  and 
Related Disorders  17: S3-10, 2011 (doi:10.1016/j.parkreldis.2011.06.019).
Additional references
[1] D.M. Simpson, M. Hallett, E.J. Ashman, C.L. Comella, M.W. Green, et al., Practice guide-
line update summary: botulinum neurotoxin for the treatment of blepharospasm,cervical 
dystonia, adult spasticity, and headache; Report of the Guideline Development 
Subcommittee of the American Academy of Neurology, Neurology 86 (2016) 1–9, http://
dx.doi.org/10.1212/WNL.0000000000002560
[2] I. Novak, S. Mcintyre, C. Morgan, L. Campbell, L. Dark, N. Morton, E. Stumbles, S. 
Wilson, S. Goldsmith: A systematic review of interventions for children with cerebral 
palsy: state of the evidence, Developmental Medicine & Child Neurology 55: 885–910, 
2013.
Botulinum Toxin Therapy Manual for Dystonia and Spasticity10
